Product ID |
Product Name |
CAS# |
Purity |
Y3285752 |
Tubulin polymerization-IN-56 |
2966790-98-5 |
99% |
Y3291645 |
PD-1/PD-L1-IN-33 |
2975602-78-7 |
99% |
Y3286655 |
CDFI |
1199797-92-6 |
99% |
Y3286034 |
M190S |
2578300-07-7 |
95% |
Y3286132 |
NLRP3 agonist 1 |
2454019-69-1 |
99% |
Y3287958 |
KY386 |
2787598-01-8 |
99% |
Y3305008 |
Cyclopropaneacetamide-Exatecan |
2414254-36-5 |
96% |
Y3296990 |
Irpagratinib |
2230974-62-4 |
99% |
Y3305984 |
HSD17B13-IN-3 |
313259-88-0 |
99% |
Y3287272 |
TRPV2-selective blocker 1 |
2242724-49-6 |
99% |
Y3294540 |
RSK4-IN-1 |
2755819-10-2 |
98% |
Y3305059 |
GPS491 |
2655502-29-5 |
98% |
Y3305745 |
HL-8 |
2766352-64-9 |
99% |
Y3298024 |
Vanzacaftor |
2374124-49-7 |
98% |
Y3286934 |
Myt1-IN-3 |
2719793-54-9 |
99% |
Y3286791 |
CQ-Lyso |
2089438-23-1 |
98% |
Y3286471 |
SN05 |
2768663-51-8 |
98% |
Y3289779 |
Vanin-1-IN-3 |
2940964-70-3 |
96% |
Y3291348 |
ALPK1-IN-1 |
2765457-72-3 |
99% |
Y3308913 |
pVEC (Cadherin-5) |
383430-30-6 |
98% |
Y3307251 |
Tripeptide-32 |
1185583-20-3 |
99% |
Y3297387 |
FOXO1-IN-3 |
2451093-95-9 |
99% |
Y3290208 |
(3ß)-3-Hydroxyoleanan-12-one |
5916-18-7 |
99% |
Y3310892 |
PKM2 inhibitor G |
904457-46-1 |
99% |
Y3308041 |
UCB7362 |
2610631-17-7 |
95% |
Y3289493 |
3-{[(tert-butoxy)carbonyl]amino}-2-[(1-methyl-1H-pyrazol-4-yl)methyl]propanoic acid |
2288072-65-9 |
95% |
Y3308755 |
methyl 3,3-difluoro-1-(methylamino)cyclobutane-1-carboxylate |
2301239-89-2 |
95% |
Y3291380 |
2-{[(tert-butoxy)carbonyl]amino}-2-(4-chlorophenyl)propanoic acid |
1408729-31-6 |
95% |
Y3243119 |
(2-aminocyclobutyl)methanol hydrochloride |
2503205-72-7 |
95% |
Y3293645 |
4-amino-5-methoxy-2-methylbenzoic acid |
854644-72-7 |
95% |
Y3289223 |
AlPhos Pd G6 OTf |
2097600-18-3 |
95% |
Y3288079 |
3-{[(tert-butoxy)carbonyl]amino}-5-(hydroxymethyl)benzoic acid |
2920154-90-9 |
95% |
Y3290470 |
tert-butyl N-(6-bromo-1H-indazol-3-yl)carbamate |
2680894-83-9 |
95% |
Y3298051 |
6-[(tert-butoxy)carbonyl]-1-cyano-6-azaspiro[2.5]octane-1-carboxylic acid |
2137697-16-4 |
95% |
Y3295294 |
rac-(1R,2S)-2-benzylcyclopropane-1-carboxylic acid |
161711-40-6 |
95% |
Y3306040 |
tert-butyl 3-[amino(phenyl)methyl]azetidine-1-carboxylate |
1823419-20-0 |
95% |
Y3295981 |
tert-butyl N-[1-(5-bromopyrimidin-2-yl)cyclobutyl]carbamate |
2135587-15-2 |
95% |
Y3287694 |
N-Methylpiperazine-d8 hydrochloride |
3029270-07-0 |
95% |
Y3310272 |
SPOP-IN-6lc |
2136270-56-7 |
99% |
Y3307294 |
A2B receptor antagonist 2 hydrochloride |
724-70-9 |
95% |
Y3306406 |
TRV-120027 acetate (1234510-46-3 free base) |
1824712-70-0 |
99% |
Y3308660 |
Phos-tag Acrylamide AAL-107 |
871839-54-2 |
98% |
Y3305297 |
LKM38 |
2103360-95-6 |
97% |
Y3309519 |
N'-(2-Chloroethyl)-N-(4-methylcyclohexyl)-N-nitrosourea |
75219-93-1 |
96% |
Y3308645 |
EPZ032597 |
1887193-58-9 |
99% |
Y3310934 |
Atecegatran TFA |
433937-75-8 |
98% |
Y3287439 |
TI17 |
1005178-02-8 |
90% |
Y3310061 |
Anidoxime HCl |
31729-11-0 |
99% |
Y3306038 |
Ralitoline |
1089085-40-4 |
98% |
Y3306414 |
Anatibant 2HCl |
209788-45-4 |
100% |
Y3295350 |
AJ2-30 |
2700322-79-6 |
95% |
Y3308291 |
(1R,5S,6r)-N-(2-methyl-1-((3-methylpyridin-2-yl)oxy)propan-2-yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide L(+)-Tartaric acid |
2919211-45-1 |
99% |
Y3307701 |
BCAT-IN-4 |
406190-85-0 |
99% |
Y3307777 |
GW297361 |
388627-21-2 |
95% |
Y3310404 |
Sabcomeline HCl |
133642-67-8 |
99% |
Y3310251 |
uk-50001 |
857900-47-1 |
99% |
Y3309841 |
Compound V007-6018 |
859093-06-4 |
98% |
Y3304671 |
CBS-1114 HCl |
33244-00-7 |
99% |
Y3310553 |
(S)-4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide |
1934246-20-4 |
99% |
Y3296060 |
sBADA |
2376838-11-6 |
95% |
Y3311405 |
SiR-COOH |
1418275-26-9 |
92% |
Y3304664 |
Atagabalin HCl |
223445-67-8 |
100% |
Y3287299 |
Fmoc-Gly-Gly-Phe-Gly-NH-CH2-O-CO-CH3 |
2866301-96-2 |
95% |
Y3312000 |
BDBM50597431 |
1629853-49-1 |
100% |
Y3305042 |
GV-150013X |
151386-96-8 |
100% |
Y3290051 |
Glucocorticoid receptor agonist-3 |
2842165-73-3 |
98% |
Y3293941 |
malonyl-NAC |
2361327-06-0 |
95% |
Y3287308 |
Glucocorticoid receptor agonist-3 Ala-Ala-Mal |
3014393-35-9 |
99% |
Y3289106 |
ALP/Carbonic anhydrase-IN-1 |
2091887-74-8 |
99% |
Y3293912 |
ON 108600 |
1585246-23-6 |
99% |
Y3293095 |
Hydroxy-PP-Me |
833481-77-9 |
99% |
Y3308393 |
BT424 |
2755180-37-9 |
98% |
Y3290867 |
Antibiofilm agent-1 |
2001602-10-2 |
95% |
Y3287098 |
Antiproliferative agent-36 |
193828-76-1 |
98% |
Y3286570 |
PAT1inh-B01 |
1775330-54-5 |
98% |
Y3289561 |
CNS-11 |
445218-34-8 |
98% |
Y3297608 |
Mcl-1 inhibitor 17 |
892250-00-9 |
98% |
Y3293593 |
SNX7886 |
2924557-42-4 |
99% |
Y3297678 |
RapaBlock |
2474076-02-1 |
98% |
Y3291203 |
Val-Cit-PAB-Exatecan |
2227350-99-2 |
99% |
Y3304608 |
(2R,3S)-Azelaprag |
2049979-31-7 |
100% |
Y3295369 |
Ficonalkib |
2233574-95-1 |
97% |
Y3297142 |
ALK5-IN-34 |
2785430-90-0 |
98% |
Y3293997 |
GPR35 agonist 5 |
2226201-24-5 |
98% |
Y3292689 |
M47 |
890808-56-7 |
99% |
Y3311781 |
(S,R,S)-AHPC-C2-PEG3-BCN |
2876198-36-4 |
98% |
Y3295379 |
XPW1 |
2700286-66-2 |
99% |
Y3293085 |
SN40 hydrochloride |
2768663-15-4 |
98% |
Y3286282 |
(R)-Vanzacaftor |
2374124-48-6 |
95% |
Y3291536 |
KPH2f |
2760615-09-4 |
98% |
Y3293514 |
UDP-glucosamine disodium |
1355005-51-4 |
99% |
Y3297847 |
(R)-IDO/TDO-IN-1 |
2033173-00-9 |
98% |
Y3288286 |
Cytarabine triphosphate trisodium |
1179343-17-9 |
99% |
Y3295366 |
CBiPES |
353235-01-5 |
95% |
Y3306413 |
(Iso)-Dehydroemetine |
2649-50-5 |
96% |
Y3311025 |
Benzonitrile, 4-[[5-cyclopropyl-3-methyl-1-[(methylsulfonyl)methyl]-1H-pyrazol-4-yl]oxy]-2,6-dimethyl- |
936345-34-5 |
98% |
Y3306556 |
ARRY-403 |
1138669-65-4 |
100% |
Y3307814 |
NF-56-EJ40 hydrochloride |
2728500-80-7 |
97% |
Y3295374 |
Pim-1 kinase inhibitor 8 |
916038-47-6 |
99% |
Y3297654 |
Dasatinib analog-1 |
1174416-41-1 |
98% |